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Abstract
Background: Increased numbers and improperly positioned centrosomes, aneuploidy or polyploidy, and chromosomal
instability are frequently observed characteristics of cancer cells. While some aspects of these events and the checkpoint
mechanisms are well studied, not all players have yet been identified. As the role of proteases other than the proteasome
in tumorigenesis is an insufficiently addressed question, we investigated the epigenetic control of the widely conserved
protease HTRA1 and the phenotypes of deregulation.
Methods: Mouse embryonal fibroblasts and HCT116 and SW480 cells were used to study the mechanism of epigenetic
silencing of HTRA1. In addition, using cell biological and genetic methods, the phenotypes of downregulation of HTRA1
expression were investigated.
Results: HTRA1 is epigenetically silenced in HCT116 colon carcinoma cells via the epigenetic adaptor protein MBD2.
On the cellular level, HTRA1 depletion causes multiple phenotypes including acceleration of cell growth,
centrosome amplification and polyploidy in SW480 colon adenocarcinoma cells as well as in primary mouse
embryonic fibroblasts (MEFs).
Conclusions: Downregulation of HTRA1 causes a number of phenotypes that are hallmarks of cancer cells
suggesting that the methylation state of the HtrA1 promoter may be used as a biomarker for tumour cells or
cells at risk of transformation.
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Background
Mammalian HtrA1 belongs to the widely conserved
high-temperature requirement A (HtrA) family of homo-
oligomeric serine proteases that are implicated in protein
quality control. The ubiquitously expressed HTRA1 is
composed of a signal sequence for secretion, a partial insu-
lin like growth factor binding protein-7 domain of un-
known function, a serine protease domain resembling
chymotrypsin and one C-terminal PDZ domain. HTRA1
has been shown to have at least three cellular locations.
The extracytoplasmic pool is involved in the homeostasis
of the extracellular matrix as HTRA1 degrades fibronectin,
fibromodulin, aggrecan and decorin. In addition, intracel-
lular HTRA1 localizes to microtubules or to the nucleus
(for review see [1]).
Human HTRA1 has been implicated in several severe
pathologies including cancer, age-related macular degener-
ation, Alzheimer’s disease, arthritis and familial ischemic
cerebral small-vessel disease [1]. In many of these diseases,
protein fragments or aggregates are either causative for
disease or are disease modifying factors that are produced
or degraded by HTRA1. Furthermore, several publications
link HTRA1 to tumorigenesis as its gene has been found
to be downregulated in many tumours [2], and forcing its
re-expression interfered with proliferation of metastatic
melanoma cells [3] and cell migration [4], suggesting a
tumour suppressor function. In addition, HTRA1 was
shown to modulate cisplatin- and paclitaxel-induced cyto-
toxicity and low levels of HTRA1 correlated with a poor
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response to drug treatment whilst higher levels of HTRA1
correlated with a higher response rate [5]. Downregulation
of the HTRA1 gene in tumour cells has been linked with
epigenetic mechanisms [2, 6] and the HTRA1 promoter was
identified as a target of the histone deacetylase HDAC1 [7].
Despite these recent advances, the function and mechanism
of silencing of intracellular HTRA1 underlying its involve-
ment in cell proliferation, migration and tumorigenesis are
currently not well understood.
We show that HTRA1 is epigenetically silenced in
HCT116 colon carcinoma cells and during early stages of
tumorigenesis in a mouse model of intestinal cancer. Down-
regulation of HTRA1 causes a multiple phenotypes that are
hallmarks of cancer cells including increased proliferation of
mouse embryonic fibroblasts (MEF), as well as chromosome
and centrosome amplifications.
Methods
Cell lines and drug treatments
This study received ethical approval from Cardiff Univer-
sity’s Animal Welfare and Ethical Review Body (previously
known as the ERP), and all animal procedures were con-
ducted in accordance with UK Home Office regulations.
HCT116, SW480 cells and MEFs were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10 % fetal bovine serum, 1 % penicillin and
1 % streptomycin at 37 °C in humidified atmosphere with
5 % CO2. MEFs were isolated from E13.5 and E14.5
embryos derived from four different breedings. Htra1−/−
mice were described previously [8]. SW480 and HCT116
cells were obtained from ATCC.
Cells were seeded at a low density for 16 h and were
treated with indicated concentrations of 5-Aza-dC (Sigma)
or 400 nM TSA (NEB) for 16 h. For drug combination
cells were treated with 5-Aza-dC for 48 h followed by
TSA for additional 16 h.
Oligonucleotides
All oligonucleotides used are listed in Additional file 1:
Table S1.
Lentiviral preparation and viral infection
Hairpin sequences directed against HTRA1 or MBD2
were cloned into the lentiviral pLKO.1puro vector using
AgeI and EcoRI. 293 T cells were transfected with lenti-
viral vectors encoding shRNAs (shHTRA1 D3 and S8) or
nonsense RNA (EV ctrl.) and lentiviral packaging vectors
pCMVΔR8.2 (gag pol) and pHITG (env). Viruses were
collected 48 h after transfection. HCT116 and SW480
cells were infected with the collected viruses twice over
18 h in the presence of polybrene. Infected cells were
selected using 1.6 μg/ml puromycin.
Confocal laser microscopy and antibodies
24 h after plating, cells were stained against α-tubulin
(Invitrogen), β-tubulin (Molecular Probes), γ-tubulin
(Sigma-Aldrich) or Actin (MP Biomedicals). For detec-
tion, secondary antibodies conjugated with Alexa-488 or
Phalloidin-TRITC (Molecular Probes) were used. Nuclei
were stained with DAPI (Molecular Probes). Samples
were analysed in a Leica TCS SL (SP5) laser confocal
microscope and Leica Confocal Software was used for
imaging. Images were taken using an HCX PL APO x 63
oil objective lens.
RNA purification and quantitative real-time-PCR (qRT-PCR)
analysis
RNA purification and qRT-PCR were done as described
[9]. All mRNA levels were normalized to mRNA levels
of the “house-keeping” gene GAPDH for samples from
human cell lines or β-actin for samples from murine cell
lines to obtain the mean normalized expression. Analysis
of data sets was carried out with Q-Gene software [10].
Karyotyping of MEFs and SW480 cells
Exponentially growing SW480 (Parental, EV ctrl. and
shHTRA1 D3 and S8) and MEF cultures were incubated in
N-deacetyl-N-methylcolchicine (Colcemid; 0.08 μg/ml) for
2 h to arrest mitotic cells in highly condensed metaphase
like stages. Monolayers were rinsed and centrifuged for
5 min at 120 g. Cell sediments were hypotonically treated
with 5 ml of 75 mM KCl for 10 min. Following centrifuga-
tion the swollen cells were gently mixed with 5 ml of fixing
solution (methanol/acetic acid; 3/1), centrifuged, and again
mixed with fixing solution. Cell suspensions were dropped
onto pre-cleaned, wet, ice-cold glass microscope slides to
obtain good spreading of the chromosome sets. After air-
drying overnight, the preparations were stained in Giemsa-
solution (5 %). Intact metaphase cells were counted for
their chromosome numbers at 1000 fold magnification (oil-
immersion).
Bisulfite modification and bisulfite sequencing PCR (BSP)
of genomic DNA
Genomic DNA was prepared from cell lines or murine
colon polyp cells using QIAamp DNA Mini Kit (Qiagen).
Bisulfite conversion of 2 μg genomic DNA was performed
using the EpiTect Bisulfite Kit (Qiagen). Origin of polyps:
no. 13 from mouse no. 444, no. 18 from mouse no. 508,
no. 22 from mouse no. 509, nos. 97, 98, 99, 101 from
mouse no. 1122 and nos. 145 & 147 from mouse no. 495.
3 μl of bisulfite treated genomic DNA were used for PCR
amplification. PCR products were purified and cloned into
pCR2.1-TOPO using TOPO TA Cloning Kit (Invitrogen).
DNA was sequenced and methylation status of the DNA
sequences was analysed using BIQAnalyzer [11].
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Chromatin immunoprecipitation (ChIP)
Confluent SW480 and HCT116 cells were used for ChIP
experiments. For immunoprecipitation, 2 μg of RNApo-
lII (Active Motif, No. 39097), IgG (Active Motif ), H3
(Abcam, No. 1791), H3K9ac (Diagenode, pAB-177-050)
and 10 μg MBD2a/b (Sigma, M7318) antibodies were
used. qRT-PCR was used to determine the enrichment
of immunoprecipitated DNA relative to the input mater-
ial using gene-specific (HTRA1) and control (GAPDH)
primer sets (Additional file 1: Table S1). For more details
see Additional file 1.
Protein purification
HTRA1 was purified as described [12]. Purified HTRA1
was dialyzed against 50 mM Tris HCl, pH 8.0, 150 mM
NaCl and stored at −70 °C. 6His tagged MBD2b,
pET28MBD2b were purified using Protino Ni-TED 2000
column (Macherey-Nagel) following manufacturer’s in-
struction. Subsequently, MBD2b fractions were dialyzed
against 50 mM NaH2PO4, pH 8.0 and stored at −70 °C.
EMSA
Electrophoretic Mobility Shift Assay was done in 10 μl
of EMSA-buffer (50 mM Tris, 5 mM MgCl2, 10 mM
DTT, pH 7.5) for 5 min at RT. Reaction mixtures were
loaded on a TBE-gel which was stained with ethidium
bromide.
Protease protection assay
Trypsin (Sigma) digests of MBD2b were performed by
incubating 5 μg MBD2b with various amounts of trypsin
for 20 min at 37 °C in reaction buffer (50 mM Tris, 5 mM
MgCl2, pH 7.5). To analyse the effect of DNA-binding,
MBD2b was pre-incubated with DNA-oligonucleotides
(Additional file 1: Table S1) at equimolar concentration
for 10 min at RT before adding trypsin.
Statistical analyses
Statistical analyses were carried out using GraphPad
Prism5 software (GraphPad Software). Gaussian distribu-
tion of data sets was tested via D’Agostino and Pearson
omnibus normality test or (for smaller n) via Komologrov
Smirnov normality test with alpha = 0.05. Data sets follow-
ing a Gaussian distribution were analysed by a two-tailed
t-test if variance homogeneity was given. A two-tailed
Mann–Whitney U test was used for analysing data sets
not following a Gaussian distribution or with significant
difference in variances (Levene-test p-value <0.2). For
analysis of nominal data sets Fisher’s exact test was
performed.
Results
HTRA1 is epigenetically silenced in HCT116 cells and in
polyps arising in ApcMin+ mice
As HTRA1 is downregulated in a range of tumours we
determined if silencing of HTRA1 occurs in cancer cell
lines by analysing methylation of the HTRA1 promoter in
two colon carcinoma cell lines (HCT116 and SW480).
These data indicate that the HTRA1 promoter is methyl-
ated in HCT116 cells but not in SW480 cells and that
promoter methylation status correlates with reduced the
expression levels of the HTRA1 gene (Fig. 1a, b). To ob-
tain further evidence for epigenetic silencing of the
HTRA1 promoter, HCT116 and SW480 cells were treated
individually or in combination with the DNA methyltrans-
ferase (DNMT) inhibitor 5-aza-deoxycytidine (5-aza-dC)
and Trichostatin A (TSA), an inhibitor of histone deacety-
lases (HDAC). Incorporation of 5-aza-dC into DNA inhibits
methylation at CpG islands by DNA methyltransferase
whereas Trichostatin A inhibits histone deacetylation by
HDAC [13, 14]. Therefore, both inhibitors promote gene ex-
pression. Consequently, changes in HTRA1 expression were
detected following treatment of HCT116 cells with either
1 μM 5-Aza-dC in combination with 400 nM TSA or 5 μM
5-Aza-dC in combination with 400 nM TSA, leading to 7
and 10 fold higher levels of expression of HTRA1, respect-
ively (Fig. 1c). In contrast, no increases were observed in
SW480 cells (Fig. 1c). In this cell line, exposure to TSA even
reduced HTRA1 expression, which may be due to the side
effect of TSA causing cell cycle arrest in colon carcinoma
cells and fibroblasts [15, 16].
To obtain in vivo evidence, we analysed Htra1 expres-
sion in the intestines of ApcMin+ mice, a well established
model of early events in intestinal tumorigenesis [17], and
in polyps of colon adenomas arising in these animals. In
the normal intestine samples, Htra1 expression was very
low but epigenetic silencing was not involved as none of
the samples contained a methylated CpG island (Fig. 2,
controls). In contrast, Htra1 expression was differentially
regulated during polyp formation and the level of Htra1
expression correlated with the degree of DNA methylation
(Fig. 2). Of 9 colonic polyps analysed, the Htra1 promoter
was unmethylated in 4 polyps (polyps 13, 22, 145 and
147), methylated in 4 polyps (polyps 18, 98, 99 and 101)
and partially methylated in one polyp (polyp 97). These
data suggest that silencing of Htra1 is occurring during
tumorigenesis in vivo.
Methyl Binding Domain protein 2 (MBD2) mediates epigenetic
silencing of Htra1
Having established epigenetic silencing of HTRA1 in vivo
and in vitro, we wished to obtain a deeper insight by iden-
tifying factors that are involved in this process. Since
MBD2 has been shown to alter tumorigenesis in ApcMin+
mice [18], we tested whether MBD2 mediates silencing of
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HTRA1 by stable knockdown of MBD2. HCT116 cells
were used for these experiments because the HTRA1 pro-
moter is epigenetically silenced in these cells. Knockdown
was done using two independent shRNAs, resulting in an
about 5 fold reduction of MBD2 expression which led to a
5 (shMBD2.1) and 10 fold (shMBD2.2) increase in HTRA1
gene expression (Fig. 3a). This effect was specific to MBD2
as levels of MBD1 and MeCP1 were unaffected by the
knockdown of MBD2 expression (not shown). These find-
ings expand published data that identified HTRA1 as a tar-
get of mouse HDAC1 [7].
To analyse methylation-dependent binding of MBD2 to
the HTRA1 promoter we performed ChIP assays in
HCT116 and SW480 cells. Primer sets were designed cov-
ering the HTRA1 promoter sequence of the methylation
analysis shown in Fig. 1a. The specificity of ChIP assays
was verified by using nonspecific IgG (binding < 0.02 %).
As a positive control, the GAPDH promoter was shown to
be equally associated with RNAPolII (data not shown).
The occupancy of MBD2 was up to 3-fold higher in
HCT116 compared to SW480 cells (Fig. 3b), whereas the
acetylation of Lys9 at histone 3, a chromatin marker for
transcriptional activity, displayed a reversed pattern (Fig. 3b).
Similar results were published in HCT116 cells, where
binding of MBD2 to the TFF2 promoter was detected along
with reduced histone acetylation levels [19]. To obtain fur-
ther evidence for MBD2 binding to the HTRA1 promoter
we purified recombinant MBD2b, a truncated version of
MBD2 lacking the N-terminal 149 residues. This variant
mediates silencing of a target promoter in cell culture [20].
To obtain a first indication of the affinity of MBD2 to the
HTRA1 promoter we performed electrophoretic mobility
shift assays using a specific sequence of 12 nucleotides
occurring at position −376 bp to −364 bp in the CpG island
of the HTRA1 promoter. These data indicated that the
12mer nucleotide bound in 1:1 stoichiometry to MBD2 in
Fig. 1 Epigenetic regulation of HTRA1 expression in HCT116 cells. a Methylation of the human HTRA1 promoter (−388 bp to −115 bp) was determined
by sequencing 4 independent clones of bisulfite treated DNA of HCT116 and SW480 cells. b Mean normalized expression (MNE) of HTRA1 in SW480 and
HCT116 cells determined by qRT-PCR (n = 3 independent cell lines, each done in triplicates, two-tailed Mann–Whitney U test, p-value <0.0001). c HTRA1
mRNA levels in HCT116 and SW480 cells following treatment with 5-Aza-dC and TSA determined by qRT-PCR. Results of one representative experiment
are shown. MNE of control was set to 1; standard deviation was calculated from triplicates
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its methylated but not in its unmethylated form (Fig. 3c).
These results are in agreement with published data report-
ing that MBD2 binds to synthetic 34mer nucleotides with
high affinity [21]. To obtain independent evidence for bind-
ing of MBD2 to HTRA1 promoter DNA, we performed
proteolytic digests of MBD2 without or with bound DNA
(Fig. 3d). This strategy was chosen as ligand binding com-
monly causes conformational changes that lead to in-
creased stability of the protein in protease assays. Trypsin
digests MBD2 in the presence and absence of DNA.
However, in the presence of DNA, several fragments of
about 6–10 kDa are protected (Fig. 3d). The size of the
prominent band corresponds to the size of the DNA bind-
ing domain of MBD2 (residues 24 through 86). Together,
these data therefore confirm that MBD2 binds to, and epi-
genetically regulates, HTRA1 in HCT116 cells.
Loss of HTRA1 causes accelerated proliferation
To investigate whether downregulation of HTRA1 might
affect cell growth, we analysed the phenotypes of Htra1
Fig. 2 Htra1 expression and methylation of the Htra1 promoter in polyps. Mean normalized expression (MNE) of Htra1 in polyps isolated from
ApcMin+ mice was determined by qRT-PCR. Methylation of the murine Htra1 promoter (−252 bp to −12 bp) was determined by sequencing 3
independent clones of bisulfite treated DNA isolated from the same polyps that were used for measuring mRNA levels by qRT-PCR. Controls are
four independent samples taken from large intestine
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+/+ and Htra1−/− MEFs generated from E14.5 mice that
expressed either wild type levels of HtrA1 or no HtrA1.
In parallel, we also generated a stable knockdown and
overproduction of HTRA1 in SW480 cells, derived from
a pool of clones, by using two independent shRNA con-
structs and plasmid p50, respectively. The knockout and
Fig. 3 MDB2 mediates silencing of the HTRA1 promoter. a Fold expression of MBD2 and HTRA1 in HCT116 cells stably downregulated by
different shRNAs (1 and 2) or random RNA sequence (nonsense RNA) compared to the vector control (set to 1). Standard deviation is indicated
(n≥ 2 independent experiments done in triplicates, two-tailed Mann–Whitney U test, p-values HTRA1 expression: shMBD2.1 = 0.0039, shMBD2.2 = 0.0028,
Nonsense RNA = 0.0028; p-values MBD2 expression: shMBD2.1 = 0.0002, shMBD2.2 = 0.0002, Nonsense RNA= 0.0034)). b ChIP analyses of MBD2 binding
the human HTRA1 promoter (−453 bp to −336 bp) in HCT116 and SW480 cells. Results are expressed as fold enrichment compared to the reference
GAPDH promoter (n = 4, 2 independent chromatin fractions, unpaired two-tailed t-test, p-value <0.001) (left). ChIP analyses of H3K9 acetylation at the
human HTRA1 promoter (−453 bp to −336 bp). Results are expressed as fold enrichment compared to the reference histone 3 (n = 3, 2 independent
chromatin fractions, unpaired two-tailed t-test, p-value <0.001) (right). c Electric mobility shift assay using methylated or unmethylated 12 bp double
stranded oligonucleotide from the CpG island of the HTRA1 promoter and purified MBD2b in equimolar concentrations (70 pmol). MBD2-DNA complex
formation was analysed on 12 % agarose gels. d Proteolysis of MBD2b by trypsin. 5 μg of purified MBD2b were incubated with the amounts of trypsin
indicated for 20 min at 37 °C. Samples were analysed on SDS PAGE (upper panel). Proteolysis of MBD2b with bound methylated oligonucleotide by
trypsin. The protected MBD2b fragment is boxed (lower panel)
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knockdown of HTRA1 on mRNA level in MEFs and
SW480 cells, respectively, was confirmed by qRT-PCR.
While Htra1−/− MEFs showed a 99.6 % depletion of
Htra1 mRNA the SW480 shHTRA1 cells had approxi-
mately 5 fold less HTRA1 mRNA compared to the
empty vector cells (Fig. 4a). Consequently, HTRA1 pro-
tein levels were decreased in Htra1−/− MEFs and SW480
cells (Fig. 4a). Note that protein levels of SW480 cells
were lower compared to MEFs. Therefore, cell culture
supernatants were used for Western blotting to visualize
protein levels of SW480 cells because levels of secreted
HTRA1 are higher compared to cytoplasmic HTRA1
[1].
To explore the physiologic effects of HTRA1 depletion,
we analysed growth curves to measure bulk proliferation
rates in MEFs indicating that Htra1−/− MEFs grew signifi-
cantly faster compared to Htra1+/+ control cells, with a
doubling time of 21 h compared to 38 h, respectively
(Fig. 4b). In contrast, SW480shHTRA1 cells showed no
significant differences in proliferation rates compared to
the empty vector control (Fig. 4b), which is probably due
to the transformed status of SW480 cancer cells. Since
increased proliferation rates are often correlated with a re-
duction in cell size and volume [22], we determined cell
volume and cell diameter in Htra1+/+ and Htra1−/− MEFs.
Indeed, the mean cell volume of Htra1−/− MEFs was
2078 fl compared to 3323 fl of Htra1+/+ MEFs and the
mean diameter of Htra1−/− MEFs was 17 μm compared
to 19 μm of Htra1+/+ MEFs (Fig. 4c). To determine any
influence upon senescence, we serially passaged both
Htra1+/+ and Htra1−/− MEFs by splitting cells 1:3 twice
per week. In 5 independent experiments, Htra1+/+
MEFs reached a senescence plateau after 12 passages
(+/− 2), however Htra1−/− MEFs continued to grow
until passage 20 (+/− 2).
Reduced HTRA1 expression drives polyploidy and correlates
with centrosome amplification
To address the question whether HTRA1 deficiency
causes elevated genomic instability, karyotyping was per-
formed to analyse chromosome numbers in Htra1+/+
and Htra1−/− MEFs as well as in SW480 and derivatives
of SW480 that were depleted for HTRA1 by using two
independent stable shRNA constructs (Fig. 5). These
data indicated that both cell lines exhibited polyploidy
with the main peaks observed being 4n and 8n instead
of 2n and a small peak of 4n in control cells (Fig. 5a, b).
Note that SW480 cancer cells are already aneuploid [23].
It has been shown previously that HTRA1 localises to
centrosomes and microtubules in PC12 and SKOV3 cells
[4, 12]. The cellular location of HTRA1 was confirmed
for SW480 cells by analysing HTRA1-mCherry con-
structs using confocal microscopy (Additional file 1:
Figure S1). Centrosomes normally nucleate microtubules
to form the spindle that is subsequently used to position
the chromosomes during cell division [24]. Since altered
microtubule formation can predispose to polyploidy
[25], we examined the location and number of centro-
somes in mitotic cells by immunofluorescence staining
using antibodies against gamma-tubulin in Htra1−/− and
Htra1+/+ MEFs. In the absence of HTRA1, an increase
in the number of centrosomes (Fig. 6a) and multipolar
spindles (Fig. 6b) were detected.
Discussion
Several proteases such as members of the ADAMTS family,
caspase 8 and trypsinogen IV are epigenetically silenced in
cancer cells [26, 27]. As the HTRA1 promoter contains a
CpG island, we hypothesised that epigenetic mechanisms
might be one way of lowering HTRA1 levels in cells. Our
data indicate that, indeed, HTRA1 is epigenetically re-
pressed in the human colorectal cell line HCT116, but not
in SW480 cells. In HCT116 cells, silencing is mediated by
the methyl binding domain protein MBD2. In addition, the
Htra1 promoter is methylated and repressed in a propor-
tion of benign polyps that develop in the ApcMin+ mouse
model of human familial adenomatous polyposis. These
data suggest that Htra1 can be a target for epigenetic
repression in intestinal neoplasia and that such targeting
might be associated with the development of a subset of
tumours. In this regard, it is significant that repression of
Htra1 is mediated by MBD2, the deficiency of which we
have previously shown to strongly suppress the majority of
adenomas in the ApcMin+ mouse [18]. The fact that aden-
omas do eventually form in this model suggests that
MBD2-mediated suppression of target genes such as Htra1
may be relevant to a subset of lesions. An implication of
these studies is that Htra1 status will influence adenoma
formation in ApcMin+ mice, a hypothesis we are currently
testing. Our findings may also have implications in the
clinic, as the methylation state of the HtrA1 promoter may
act as a convenient biomarker for tumour cells or cells at
risk of transformation.
To investigate the mechanistic consequences of HTRA1
repression in tumorigenesis, we have analysed the pheno-
type of loss of function in both MEFs and SW480 cells.
Remarkably, we find multiple phenotypes including in-
creased proliferation, delayed onset of senescence, per-
turbed centrosome number and positioning, and ultimately
polyploidy. Tight control of all aspects of cell division
including accurate chromosome replication and partition-
ing as well as of proliferation rates is clearly critical
to both tissue homeostasis and tumour suppression.
Mechanistically, the changes we observe implicate a
number of different pathways. The delayed onset of
senescence suggests a failure in DNA damage check-
point activation, as senescence can be triggered when
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Fig. 4 Increased proliferation after HTRA1 depletion. a HTRA1 expression measured by qRT-PCR (n= 2 independent experiments, each assayed in triplicate)
and Western blots. Upper panel, Htra1+/+ and Htra1−/− MEFs (two-tailed Mann–Whitney U test, p-value <0.0001). Lower panel, supernatants of parental or
stably transfected SW480 cells (Par, untransfected SW480; overprod., SW480 stably transfected with plasmid p50HTRA1; EV ctrl., corresponding empty
vector control; shD3, downregulated via shHTRA1 D3; shS8, downregulated via shHTRA1 S8; two-tailed Mann–Whitney U test, p-values: EV ctrl. = 0.3776,
shD3 = 0.005, shS8 = 0.005). Actin was used as loading control for cell lysates (right). b Growth curves. Left panel, MEFs. 3x105 cells were placed in 6 cm
dishes and numbers of cells were counted at the time points indicated. Right panel, SW480 derivatives. 2.5x104 cells were placed into 6-wells and
numbers of cells were counted at time points indicated. (n = 2 independent experiments, standard deviations are indicated). c Mean diameter and
volume of Htra1+/+ and Htra1−/− MEFs (unpaired two-tailed t-test, p-value <0.0001)
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telomeres are eroded and generate a DNA damage
signal [28].
A second major phenomenon we observe is the deregu-
lation of centrosomes and polyploidy. The perturbation of
both centrosome position and number strongly implies a
defect in microtubule function in the absence of HTRA1,
as centrosomes normally nucleate microtubules to form
the spindle, which is subsequently used to position the
chromosomes during division. Such altered microtubules
can predispose to polyploidisation. Thus, normal cells
complete mitosis and enter S phase following activation of
cyclin-dependent kinases in G1. However, if microtubule
dynamics become perturbed, cells can aberrantly exit
mitosis and enter S phase with a >4n DNA content, a
process known as endoreduplication, ultimately resulting
in polyploidy. This model is supported by the literature
showing that HTRA1 is localised to microtubules and is a
regulator of microtubule stability [4, 29, 30].
While these models offer initial explanations for some
of the detected phenotypes of cells depleted for HTRA1,
the underlying molecular mechanisms leading to in-
creased proliferation rates, reduced cell size and the de-
layed senescence of primary Htra1−/− MEFs remain to be
identified. While it is likely that the loss of cell cycle
checkpoint functions contributes, it is probably not the
only reason. Due to the complexity of the cell cycle mech-
anism and of cellular transformation it will be interesting
to address for example the interconnectivity of different
Fig. 5 Increased polyploidy in Htra1−/− MEFs and SW480shHTRA1 cells. a Chromosome numbers of Htra1−/− and Htra1+/+ MEFs. 50 mitotic cells were
analysed by standard karyotyping. The normal set of chromosomes is 40. Shown is the distribution of chromosome numbers (left panel) as well as
the mean number (right panel, two-tailed Mann–Whitney U test, p-value <0.01). b 50 mitotic SW480 cells were analysed by standard karyotyping. The
normal set of chromosomes is 56–58. (Par, untransfected SW480; shS8 or D3, SW480 with HTRA1 downregulated via two independent shRNAs; EV ctrl.,
corresponding to control carrying nonsense shRNA). The distribution of chromosome numbers (left panel) and the mean number (right panel, two-
tailed Mann–Whitney U test, p-values: EV ctrl. = 0,7790, shD3 < 0.0001, shS8 < 0.0001) are shown
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checkpoints, the differential expression of HTRA1 in spe-
cific cell cycle phases and its role in regulating centrosome
numbers and assembly in future experiments. Another
key open question is the regulation of HTRA1 activity in
mammalian cells. Previous studies revealed that HtrA pro-
teases reversibly switch from the inactive into the active
conformation and that this switch is mediated by specific
peptidic ligands [1]. The identification of native modulators
Fig. 6 Disturbed spindle formation and centrosome abnormalities in HTRA1 depleted cells. a Representative images of Htra1+/+ and Htra1−/− MEFs. MEFs
were grown on collagen coated glass slides, synchronised and analysed during mitosis by laser confocal microscopy. Centrosomes were visualised by
anti-γ-tubulin antibody using an Alexa488 conjugated secondary antibody. Nuclei were counterstained with DAPI. Scale bar is 25 μm (upper panel). The
number of centrosomes were counted in 50 Htra1+/+ and Htra1−/− MEFs, respectively (lower panel). For statistical analysis, data were classified into two
sets (2 and >2 centrosomes per cell) and analysed via Fisher’s exact test (p-value = 0.0041). b Representative images of immunofluorescence staining with
an α-tubulin antibody using an Alexa488 conjugated secondary antibody in primary Htra1+/+ and Htra1−/− MEFs (Passage 8). Nuclei were counterstained
by DAPI. Scale bar is 25 μm
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of HTRA1s activity (i.e. activators and inhibitors) and the
exact circumstances under which these regulators are oc-
curring will provide important insights into how this prote-
ase is implicated in the regulation of proliferation.
Conclusions
These data show that MBD2-dependent epigenetic silen-
cing of HTRA1 can occur during tumour development.
The phenotypes of reduced HTRA1 expression such as
acceleration of cell growth, centrosome amplification and
polyploidy provide additional support for the model that
proteolytic events are implicated in cancer biology. More-
over, the methylation state of the HTRA1 promoter may
be explored as a potential biomarker for tumour cells or
cells at risk of transformation.
Additional file
Additional file 1: contains Supplementary method (Chromatin
immunoprecipitation) and Table S1 (oligonucleotides used). Additional
figure shows colocalisation of HTRA1 and microtubules in SW480 cells.
(ZIP 394 kb)
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